Proposed approval of the new active constituent, fluralaner, and registration of Bravecto Fluralaner Chewable Tablets for Dogs

This consultation closed on 30 December 2014.
Consultation period: 
2 December 2014 to 30 December 2014

The APVMA is considering applications for the approval of the new active constituent, fluralaner, and the registration of five new products, Bravecto 1400 mg Fluralaner Chewable Tablets for Very Large Dogs, Bravecto 1000 mg Fluralaner Chewable Tablets for Large Dogs, Bravecto 500 mg Fluralaner Chewable Tablets for Medium Dogs, Bravecto 250 mg Fluralaner Chewable Tablets for Small Dogs and Bravecto 112.5 mg Fluralaner Chewable Tablets for Very Small Dogs, containing the new active constituent. The products are to be used for the treatment and prevention of flea infestations and ticks on dogs and puppies.

We invite comment from 2 December 2014 to 30 December 2014 on whether the applications for the approval of the active constituent and registration of the products should be granted.

For more information, see page 4 of Gazette No. 24, 2 December 2014

Please send your written submission by email, post or fax to:

Enquiries
Australian Pesticides and Veterinary Medicines Authority
PO Box 6182
Kingston ACT 2604

Phone: +61 2 6210 4701
Fax: +61 2 6210 4721
Email: enquiries@apvma.gov.au  

To protect your privacy, please do not include contact information in your feedback. If you would like a response, please contact us.